HOME » News & Media

    Vyome Therapeutics expects data from its anti-biotic resistant acne drug end of 2019


    Feb. 11, 2019 (Proactive Investors USA) -- Vyome Therapeutics Inc CEO Venkat Nelabhotla sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

    Vyome Therapeutics is a clinical stage speciality pharmaceutical company, with platform technologies and a pipeline of drugs for antibiotic-resistant acne and other skin pathogens.

    Source: proactiveinvestorsusa.com

    Visit: www.vyome.in
    Copyright © 2021 Vyome Biosciences Private Limited.

    Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.